Advertisement

Spasmolytika

  • Ulrich Schwabe

Zusammenfassung

Wie in den vergangenen Jahren sind die Verordnungen der Spasmolytika 2003 weiter zurückgegangen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Dickinson RG, Baker PV, Franklin ME, Hooper WD (1991): Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. J Pharm Sci 80: 952–957.PubMedCrossRefGoogle Scholar
  2. Duggan JM (1965): A controlled trial of an anticholinergic drug, pipenzolate methylbromide („piptal“), in the management of peptic ulcer. Med J Aust 2: 826–827.PubMedGoogle Scholar
  3. Fennerty MB (2003): Traditional therapies for irritable bowel Syndrome: an evidence-based appraisal. Rev Gastroenterol Disord 3(suppl 2): S18–S24.PubMedGoogle Scholar
  4. Garrett ER, Venitz J, Eberst K, Cerda JJ (1993): Pharmacokinetics and bioavailabilities of hymecromone in human volunteers. Biopharm Drug Dispos 14:13–39.PubMedCrossRefGoogle Scholar
  5. Heistermann HP, Krawzak H-W, Andrejeweski K, Hohlbach G (1997): Pharmakologische Beeinflussung der postprandialen Gallengangskinetik — Sonographische Lumenmessung des Gallenganges. Ultraschall in Med 18:84–87.CrossRefGoogle Scholar
  6. Hoffmann J, Badenberg B, Day U-H, Garanin G, Lohr E (1986): Hymecromon bei funktionellen Gallenwegsstörungen. Med Welt 37:1593–1598.Google Scholar
  7. Klein KB (1988): Controlled treatment trials in the irritable bowel Syndrome: a critique. Gastroenterology 95:232–241.PubMedGoogle Scholar
  8. Kline RM, Kline JJ, Di Palma J, Barbero GJ (2001): Enteric-coated, pH-dependent peppermint oil capsules for the treatment of iffitable bowel Syndrome in children. J Pediatr 138:125–128.PubMedCrossRefGoogle Scholar
  9. Kruis W, Weinzierl M, Schüssler P, Holl J (1986): Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel Syndrome. Digestion 34:196–201.PubMedCrossRefGoogle Scholar
  10. Pittler MH, Ernst E (1998): Peppermint oil for irritable bowel Syndrome: a critical review and metaanalysis. Am J Gastroenterol 93:1131–1135.PubMedCrossRefGoogle Scholar
  11. Poynard T, Regimbeau C, Benhamou Y (2001): Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel Syndrome. Aliment Pharmacol Ther 15: 355–361.PubMedCrossRefGoogle Scholar
  12. Schäfer E, Ewe K (1990): Behandlung des Colon irritabile. Wirksamkeit und Verträglichkeit von Buscopan plus, Buscopan, Paracetamol und Plazebo bei ambulanten Patienten mit Colon irritabile. Fortschr Med 108:488–492.PubMedGoogle Scholar
  13. Schmieder G, Stankov G, Zerle G, Schinzel S, Brune K (1993): Observer-blind study with metamizole versus tramadol and butylscopolamine in acute biliary colic pain. Arzneim Forsch 43:1216–1221.Google Scholar
  14. Sommers DK, Snyman JR, van Wyk M, Eloff JN (1997): Lack of bioavailability of mebeverine even after pretreatment with pyridostigmine. Eur J Clin Pharmacol 53: 247–249.PubMedCrossRefGoogle Scholar
  15. Tahir KI (1992): Return to Pakistan of pipenzolate plus phenobarbitone. Lancet 339: 498.PubMedCrossRefGoogle Scholar
  16. Talley NJ (2003): Evaluation of drug treatment in irritable bowel Syndrome. Br J Clin Pharmacol 56: 362–369.PubMedCrossRefGoogle Scholar
  17. Vincent PC, Fenton BH, Beeston D (1967): The effect of pipenzolate on gastric secretion in man. Med J Aust 1: 546–548.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations